TrialBMJ open respiratory research2026

Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA.

Mohd Nubli Mustapa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.